The frequent mutation Gly/Asp in CDR1H may determine a cross-reactive idiotope in anti-I cold agglutinins

C. Abatangelo, Lilian Plotkin, I. Mathov, L. Squiquera, J. Leoni

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Variable domains (V(H)) of all known anti i/I cold agglutinin (CA) heavy chains are codified by the V(H)4-21 gene. While anti-i CAs are the expression of gene rearrangement without mutations represented by amino acid changes, anti-1 CAs present, among others, a frequent somatic mutation of Gly by Asp at position 31. The hydropathy profile calculated for the CDR1H (position 30 to position 35), as well as some adjacent positions of the heavy chain belonging to anti-i and anti-I antibodies, showed the conformational changes accompanying the replacement of Gly by Asp. A MoAb (LP91), which had been obtained in BALB/c mice immunized with a Fabμ fragment from a monoclonal IgMκIIIb anti-I CA (protein KAU), proved capable of inhibiting human adult erythrocyte cryoagglutination by anti-I CAs but not that of fetal erythrocytes by anti-i CAs. Western blot analysis disclosed that such MoAbs recognized a sequential epitope located in the Fd fragment of all anti-I CAs employed in this study. With the purpose of checking whether Asp31 was involved in the epitope recognized by the MoAb, two peptides, D and G, were synthesized which mimicked the CDR1H structure of anti-I and anti-i, respectively; the MoAb only reacted with peptide D by ELISA. Subsequent experimental results indicate that the Gly/Asp mutation could be associated with the diverse specificity presented by these autoantibodies, a change determining a characteristic epitope/idiotope, recognized by LP91 in the CDR1H.

Original languageEnglish (US)
Pages (from-to)185-190
Number of pages6
JournalClinical and Experimental Immunology
Volume104
Issue number1
StatePublished - 1996
Externally publishedYes

Fingerprint

Epitopes
Mutation
Erythrocytes
Peptides
Immunoglobulin Fab Fragments
Gene Rearrangement
Viperidae
Autoantibodies
Anti-Idiotypic Antibodies
Western Blotting
Enzyme-Linked Immunosorbent Assay
Amino Acids
Genes
cold agglutinins
Proteins
Fd immunoglobulins

Keywords

  • autoimmunity
  • CDR1H
  • cold agglutinins
  • public idiotope
  • synthetic peptides

ASJC Scopus subject areas

  • Immunology

Cite this

The frequent mutation Gly/Asp in CDR1H may determine a cross-reactive idiotope in anti-I cold agglutinins. / Abatangelo, C.; Plotkin, Lilian; Mathov, I.; Squiquera, L.; Leoni, J.

In: Clinical and Experimental Immunology, Vol. 104, No. 1, 1996, p. 185-190.

Research output: Contribution to journalArticle

@article{06f9d288a9764fa29ed2e853cc17b412,
title = "The frequent mutation Gly/Asp in CDR1H may determine a cross-reactive idiotope in anti-I cold agglutinins",
abstract = "Variable domains (V(H)) of all known anti i/I cold agglutinin (CA) heavy chains are codified by the V(H)4-21 gene. While anti-i CAs are the expression of gene rearrangement without mutations represented by amino acid changes, anti-1 CAs present, among others, a frequent somatic mutation of Gly by Asp at position 31. The hydropathy profile calculated for the CDR1H (position 30 to position 35), as well as some adjacent positions of the heavy chain belonging to anti-i and anti-I antibodies, showed the conformational changes accompanying the replacement of Gly by Asp. A MoAb (LP91), which had been obtained in BALB/c mice immunized with a Fabμ fragment from a monoclonal IgMκIIIb anti-I CA (protein KAU), proved capable of inhibiting human adult erythrocyte cryoagglutination by anti-I CAs but not that of fetal erythrocytes by anti-i CAs. Western blot analysis disclosed that such MoAbs recognized a sequential epitope located in the Fd fragment of all anti-I CAs employed in this study. With the purpose of checking whether Asp31 was involved in the epitope recognized by the MoAb, two peptides, D and G, were synthesized which mimicked the CDR1H structure of anti-I and anti-i, respectively; the MoAb only reacted with peptide D by ELISA. Subsequent experimental results indicate that the Gly/Asp mutation could be associated with the diverse specificity presented by these autoantibodies, a change determining a characteristic epitope/idiotope, recognized by LP91 in the CDR1H.",
keywords = "autoimmunity, CDR1H, cold agglutinins, public idiotope, synthetic peptides",
author = "C. Abatangelo and Lilian Plotkin and I. Mathov and L. Squiquera and J. Leoni",
year = "1996",
language = "English (US)",
volume = "104",
pages = "185--190",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - The frequent mutation Gly/Asp in CDR1H may determine a cross-reactive idiotope in anti-I cold agglutinins

AU - Abatangelo, C.

AU - Plotkin, Lilian

AU - Mathov, I.

AU - Squiquera, L.

AU - Leoni, J.

PY - 1996

Y1 - 1996

N2 - Variable domains (V(H)) of all known anti i/I cold agglutinin (CA) heavy chains are codified by the V(H)4-21 gene. While anti-i CAs are the expression of gene rearrangement without mutations represented by amino acid changes, anti-1 CAs present, among others, a frequent somatic mutation of Gly by Asp at position 31. The hydropathy profile calculated for the CDR1H (position 30 to position 35), as well as some adjacent positions of the heavy chain belonging to anti-i and anti-I antibodies, showed the conformational changes accompanying the replacement of Gly by Asp. A MoAb (LP91), which had been obtained in BALB/c mice immunized with a Fabμ fragment from a monoclonal IgMκIIIb anti-I CA (protein KAU), proved capable of inhibiting human adult erythrocyte cryoagglutination by anti-I CAs but not that of fetal erythrocytes by anti-i CAs. Western blot analysis disclosed that such MoAbs recognized a sequential epitope located in the Fd fragment of all anti-I CAs employed in this study. With the purpose of checking whether Asp31 was involved in the epitope recognized by the MoAb, two peptides, D and G, were synthesized which mimicked the CDR1H structure of anti-I and anti-i, respectively; the MoAb only reacted with peptide D by ELISA. Subsequent experimental results indicate that the Gly/Asp mutation could be associated with the diverse specificity presented by these autoantibodies, a change determining a characteristic epitope/idiotope, recognized by LP91 in the CDR1H.

AB - Variable domains (V(H)) of all known anti i/I cold agglutinin (CA) heavy chains are codified by the V(H)4-21 gene. While anti-i CAs are the expression of gene rearrangement without mutations represented by amino acid changes, anti-1 CAs present, among others, a frequent somatic mutation of Gly by Asp at position 31. The hydropathy profile calculated for the CDR1H (position 30 to position 35), as well as some adjacent positions of the heavy chain belonging to anti-i and anti-I antibodies, showed the conformational changes accompanying the replacement of Gly by Asp. A MoAb (LP91), which had been obtained in BALB/c mice immunized with a Fabμ fragment from a monoclonal IgMκIIIb anti-I CA (protein KAU), proved capable of inhibiting human adult erythrocyte cryoagglutination by anti-I CAs but not that of fetal erythrocytes by anti-i CAs. Western blot analysis disclosed that such MoAbs recognized a sequential epitope located in the Fd fragment of all anti-I CAs employed in this study. With the purpose of checking whether Asp31 was involved in the epitope recognized by the MoAb, two peptides, D and G, were synthesized which mimicked the CDR1H structure of anti-I and anti-i, respectively; the MoAb only reacted with peptide D by ELISA. Subsequent experimental results indicate that the Gly/Asp mutation could be associated with the diverse specificity presented by these autoantibodies, a change determining a characteristic epitope/idiotope, recognized by LP91 in the CDR1H.

KW - autoimmunity

KW - CDR1H

KW - cold agglutinins

KW - public idiotope

KW - synthetic peptides

UR - http://www.scopus.com/inward/record.url?scp=0029867699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029867699&partnerID=8YFLogxK

M3 - Article

VL - 104

SP - 185

EP - 190

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 1

ER -